[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100455488":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":32,"responsibleParty":48,"collaborators":50,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":10,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aggressive hydration",null,"Patients with greater than or equal to 2 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period",[13],"Other: IV fluids",{"label":15,"type":10,"description":16,"interventionNames":17},"Conservative hydration","Patients with less than 1 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"IV fluids","Amount of intravenous fluids delivered",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Nauzer Forbes, MD MSc","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","403-592-5089","nauzer.forbes@ucalgary.ca",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Peter Lougheed Hospital","RECRUITING","Calgary","Alberta","Canada","CA",{"type":41,"coordinates":42},"Point",[43,44],-114.08529,51.05011,{"lat":44,"lon":43},[47],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51,53,55,57,60],{"name":52,"class":6},"McGill University",{"name":54,"class":6},"University of Ottawa",{"name":56,"class":6},"Queen's University",{"name":58,"class":59},"Halton Health (Oakville)","UNKNOWN",{"name":61,"class":6},"Island Health, Victoria, BC","100455488","iv-fluids-and-post-ercp-pancreatitis-100455488",false,"NCT05211206","IV Fluids and Post-ERCP Pancreatitis","Association Between Peri-procedural Intravenous Hydration and Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Inclusion Criteria:\n\n* Subject referred for ERCP, regardless of indication;\n* Subject age 18 years or older;\n* Subject able to give informed consent to involvement be included.\n\nExclusion Criteria:\n\n* Subject has a standard contraindication to ERCP;\n* Subject or surrogate unable or unwilling to provide informed consent;\n* Subject age \\\u003C 18 years.","ALL","18 Years",{"count":72,"type":73},13000,"ESTIMATED","OBSERVATIONAL","Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).",[77],"ERCP","2026-04-28",{"date":80,"type":81},"2026-04-29","ACTUAL",{"date":83,"type":81},"2022-01-10",{"date":85,"type":73},"2027-06-30",{"name":5,"class":6},1]